Global Uterine Fibroid Treatment Drugs Market Size study & Forecast, By Drug Class (Gonadotropin-releasing Hormone (GnRH) Agonists, Gonadotropin-releasing Hormone (GnRH) Antagonists, Progestin-releasing Intrauterine Device (IUD) & Contraceptives, Non-hormonal Medications, Others), By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids), By End-user (Hospital Pharmacies, Retail Pharmacies, other) and Regional Analysis, 2023-2030
Global Uterine Fibroid Treatment Drugs Market is valued at approximately USD 1.80 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 10.2% over the forecast period 2023-2030. The Uterine Fibroid Treatment Drugs are specifically developed to treat uterine fibroid, which are benign tumors that grow in the uterus. This is a common noncancerous condition affecting the uterus in women of reproductive age. The Uterine Fibroid Treatment Drugs market is being driven by factors such as the increasing number of new product launches and the rising prevalence of uterine fibroids.
These drugs include GnRH agonists, progestin-releasing IUDs, SPRMs, NSAIDs, and tranexamic acid, which aim to reduce fibroid size, manage symptoms such as heavy bleeding and pain, or both. On June 2022, Yselty, an oral GnRH antagonist was authorized by the EMA for the treatment of moderate to severe symptoms of uterine leiomyomas. GnRH antagonist, Myfembree, was authorised by the U.S. FDA for the treatment of heavy bleeding associated with uterine fibroids. along with that on May 2021, Myovant Sciences and Pfizer obtained U.S. FDA approval for Myfembree (relugolix), a medication specifically indicated for the treatment of heavy bleeding associated with uterine fibroids. The effectiveness of these newly launched drugs creates the growth of the market. In addition, the Growing awareness among women about uterine fibroids treatment and various governments working on early fibroids detection and treatment may create lucrative opportunities in the market. However, the high cost of fibroid treatment drugs is hindering the growth of the market.
The key regions considered for the Global Uterine Fibroid Treatment Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the rising prevalence of uterine fibroids, increasing case of pregnancy complications due to fibroids, and approval of novel treatment options. Asia Pacific is considered the fastest-growing region during the forecasted period due to the presence of two massively populated countries such as India and China. Global companies are entering into agreement with local player for the development and commercialization of therapies in the region.
Major market player included in this report are:
Myovant Sciences GmbH
Pfizer Inc.
Abbvie, Inc.
Ferring B.V.
AstraZeneca
Bayer AG
Amring Pharmaceuticals Inc.
Watson Pharma, Inc.
Boston scientific corporation
Gynesonics Inc.
Recent Developments in the Market:
• On May 2021, Myovant Sciences and Pfizer Inc. announces that the United States Food and Drug Administration (FDA) had approved MYFEMBREE, the first regular or Myfembree (relugolix) is an FDA-approved, once-daily treatment designed to manage heavy menstrual bleeding in premenopausal women with uterine fibroids, and it can be used for up to 24 months.
• On February 2021, Pfizer and Myovant release favorable results from the Phase III LIBERTY 1 and LIBERTY 2 investigations. In women with uterine fibroids, the companies are testing a once-daily combination treatment of relugolix plus estradiol and norethindrone acetate.
Global Uterine Fibroid Treatment Drugs Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered – Drug class, Type, End user, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Customization Scope - Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug class:
Gonadotropin-releasing Hormone (GnRH) Agonists
Gonadotropin-releasing Hormone (GnRH) Antagonists
Progestin-releasing Intrauterine Device (IUD) & Contraceptives
Non-hormonal Medications
Others
By Type:
Subserosal Fibroids
Intramural Fibroids
Submucosal Fibroids
Pedunculated Fibroids
By End user:
Hospital Pharmacies
Retail Pharmacies
Other
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa
These drugs include GnRH agonists, progestin-releasing IUDs, SPRMs, NSAIDs, and tranexamic acid, which aim to reduce fibroid size, manage symptoms such as heavy bleeding and pain, or both. On June 2022, Yselty, an oral GnRH antagonist was authorized by the EMA for the treatment of moderate to severe symptoms of uterine leiomyomas. GnRH antagonist, Myfembree, was authorised by the U.S. FDA for the treatment of heavy bleeding associated with uterine fibroids. along with that on May 2021, Myovant Sciences and Pfizer obtained U.S. FDA approval for Myfembree (relugolix), a medication specifically indicated for the treatment of heavy bleeding associated with uterine fibroids. The effectiveness of these newly launched drugs creates the growth of the market. In addition, the Growing awareness among women about uterine fibroids treatment and various governments working on early fibroids detection and treatment may create lucrative opportunities in the market. However, the high cost of fibroid treatment drugs is hindering the growth of the market.
The key regions considered for the Global Uterine Fibroid Treatment Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the rising prevalence of uterine fibroids, increasing case of pregnancy complications due to fibroids, and approval of novel treatment options. Asia Pacific is considered the fastest-growing region during the forecasted period due to the presence of two massively populated countries such as India and China. Global companies are entering into agreement with local player for the development and commercialization of therapies in the region.
Major market player included in this report are:
Myovant Sciences GmbH
Pfizer Inc.
Abbvie, Inc.
Ferring B.V.
AstraZeneca
Bayer AG
Amring Pharmaceuticals Inc.
Watson Pharma, Inc.
Boston scientific corporation
Gynesonics Inc.
Recent Developments in the Market:
• On May 2021, Myovant Sciences and Pfizer Inc. announces that the United States Food and Drug Administration (FDA) had approved MYFEMBREE, the first regular or Myfembree (relugolix) is an FDA-approved, once-daily treatment designed to manage heavy menstrual bleeding in premenopausal women with uterine fibroids, and it can be used for up to 24 months.
• On February 2021, Pfizer and Myovant release favorable results from the Phase III LIBERTY 1 and LIBERTY 2 investigations. In women with uterine fibroids, the companies are testing a once-daily combination treatment of relugolix plus estradiol and norethindrone acetate.
Global Uterine Fibroid Treatment Drugs Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered – Drug class, Type, End user, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Customization Scope - Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug class:
Gonadotropin-releasing Hormone (GnRH) Agonists
Gonadotropin-releasing Hormone (GnRH) Antagonists
Progestin-releasing Intrauterine Device (IUD) & Contraceptives
Non-hormonal Medications
Others
By Type:
Subserosal Fibroids
Intramural Fibroids
Submucosal Fibroids
Pedunculated Fibroids
By End user:
Hospital Pharmacies
Retail Pharmacies
Other
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa
CHAPTER 1. EXECUTIVE SUMMARY
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
1.2.1. Uterine fibroid treatment drugs Market, by Region, 2020-2030 (USD Billion)
1.2.2. Uterine fibroid treatment drugs Market, by Drug Class, 2020-2030 (USD Billion)
1.2.3. Uterine fibroid treatment drugs Market, by Type, 2020-2030 (USD Billion)
1.2.4. Uterine fibroid treatment drugs Market, by End User, 2020-2030 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET DEFINITION AND SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET DYNAMICS
3.1. Uterine fibroid treatment drugs Market Impact Analysis (2020-2030)
3.1.1. Market Drivers
3.1.1.1. Increasing number of new product launches
3.1.1.2. Rising prevalence of uterine fibroid
3.1.2. Market Challenges
3.1.2.1. High Cost of Uterine fibroid treatment drugs
3.1.3. Market Opportunities
3.1.3.1. Growing awareness of uterine fibroid in women
3.1.3.2. Government focus on early detection of uterine and treatment
CHAPTER 4. GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter’s 5 Force Impact Analysis
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. COVID-19 Impact Analysis
4.7. Disruptive Trends
4.8. Industry Expert Perspective
4.9. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET, BY DRUG CLASS
5.1. Market Snapshot
5.2. Global Uterine fibroid treatment drugs Market by Drug Class, Performance - Potential Analysis
5.3. Global Uterine fibroid treatment drugs Market Estimates & Forecasts by Drug Class 2020-2030 (USD Billion)
5.4. Uterine fibroid treatment drugs Market, Sub Segment Analysis
5.4.1. Gonadotropin-releasing Hormone (GnRH) Agonists
5.4.2. Gonadotropin-releasing Hormone (GnRH) Antagonists
5.4.3. Progestin-releasing Intrauterine Device (IUD) & Contraceptives
5.4.4. Non-hormonal Medications
5.4.5. Others
CHAPTER 6. GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET, BY TYPE
6.1. Market Snapshot
6.2. Global Uterine fibroid treatment drugs Market by Type, Performance - Potential Analysis
6.3. Global Uterine fibroid treatment drugs Market Estimates & Forecasts by Type 2020-2030 (USD Billion)
6.4. Uterine fibroid treatment drugs Market, Sub Segment Analysis
6.4.1. Subserosal Fibroids
6.4.2. Intramural Fibroids
6.4.3. Submucosal Fibroids
6.4.4. Pedunculated Fibroids
CHAPTER 7. GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET, BY END USER
7.1. Market Snapshot
7.2. Global Uterine fibroid treatment drugs Market by End User, Performance - Potential Analysis
7.3. Global Uterine fibroid treatment drugs Market Estimates & Forecasts by End User 2020-2030 (USD Billion)
7.4. Uterine fibroid treatment drugs Market, Sub Segment Analysis
7.4.1. Hospitals
7.4.2. Retail pharmacies
7.4.3. Other
CHAPTER 8. GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET, REGIONAL ANALYSIS
8.1. Top Leading Countries
8.2. Top Emerging Countries
8.3. Uterine fibroid treatment drugs Market, Regional Market Snapshot
8.4. North America Uterine fibroid treatment drugs Market
8.4.1. U.S. Uterine fibroid treatment drugs Market
8.4.1.1. Drug Class breakdown estimates & forecasts, 2020-2030
8.4.1.2. Type breakdown estimates & forecasts, 2020-2030
8.4.1.3. End User breakdown estimates & forecasts, 2020-2030
8.4.2. Canada Uterine fibroid treatment drugs Market
8.5. Europe Uterine fibroid treatment drugs Market Snapshot
8.5.1. U.K. Uterine fibroid treatment drugs Market
8.5.2. Germany Uterine fibroid treatment drugs Market
8.5.3. France Uterine fibroid treatment drugs Market
8.5.4. Spain Uterine fibroid treatment drugs Market
8.5.5. Italy Uterine fibroid treatment drugs Market
8.5.6. Rest of Europe Uterine fibroid treatment drugs Market
8.6. Asia-Pacific Uterine fibroid treatment drugs Market Snapshot
8.6.1. China Uterine fibroid treatment drugs Market
8.6.2. India Uterine fibroid treatment drugs Market
8.6.3. Japan Uterine fibroid treatment drugs Market
8.6.4. Australia Uterine fibroid treatment drugs Market
8.6.5. South Korea Uterine fibroid treatment drugs Market
8.6.6. Rest of Asia Pacific Uterine fibroid treatment drugs Market
8.7. Latin America Uterine fibroid treatment drugs Market Snapshot
8.7.1. Brazil Uterine fibroid treatment drugs Market
8.7.2. Mexico Uterine fibroid treatment drugs Market
8.8. Middle East & Africa Uterine fibroid treatment drugs Market
8.8.1. Saudi Arabia Uterine fibroid treatment drugs Market
8.8.2. South Africa Uterine fibroid treatment drugs Market
8.8.3. Rest of Middle East & Africa Uterine fibroid treatment drugs Market
CHAPTER 9. COMPETITIVE INTELLIGENCE
9.1. Key Company SWOT Analysis
9.1.1. Company
9.1.2. Company
9.1.3. Company
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Myovant Sciences Gmbh
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Recent Developments
9.3.2. Pfizer Inc.
9.3.3. Abbvie Inc.
9.3.4. Ferring B.v
9.3.5. AstraZeneca
9.3.6. Bayer AG
9.3.7. Amring Pharmaceuticals Inc.
9.3.8. Watson Pharma Inc.
9.3.9. Boston scientific corporation
9.3.10. Gynesonics Inc.
CHAPTER 10. RESEARCH PROCESS
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
1.2.1. Uterine fibroid treatment drugs Market, by Region, 2020-2030 (USD Billion)
1.2.2. Uterine fibroid treatment drugs Market, by Drug Class, 2020-2030 (USD Billion)
1.2.3. Uterine fibroid treatment drugs Market, by Type, 2020-2030 (USD Billion)
1.2.4. Uterine fibroid treatment drugs Market, by End User, 2020-2030 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET DEFINITION AND SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET DYNAMICS
3.1. Uterine fibroid treatment drugs Market Impact Analysis (2020-2030)
3.1.1. Market Drivers
3.1.1.1. Increasing number of new product launches
3.1.1.2. Rising prevalence of uterine fibroid
3.1.2. Market Challenges
3.1.2.1. High Cost of Uterine fibroid treatment drugs
3.1.3. Market Opportunities
3.1.3.1. Growing awareness of uterine fibroid in women
3.1.3.2. Government focus on early detection of uterine and treatment
CHAPTER 4. GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter’s 5 Force Impact Analysis
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. COVID-19 Impact Analysis
4.7. Disruptive Trends
4.8. Industry Expert Perspective
4.9. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET, BY DRUG CLASS
5.1. Market Snapshot
5.2. Global Uterine fibroid treatment drugs Market by Drug Class, Performance - Potential Analysis
5.3. Global Uterine fibroid treatment drugs Market Estimates & Forecasts by Drug Class 2020-2030 (USD Billion)
5.4. Uterine fibroid treatment drugs Market, Sub Segment Analysis
5.4.1. Gonadotropin-releasing Hormone (GnRH) Agonists
5.4.2. Gonadotropin-releasing Hormone (GnRH) Antagonists
5.4.3. Progestin-releasing Intrauterine Device (IUD) & Contraceptives
5.4.4. Non-hormonal Medications
5.4.5. Others
CHAPTER 6. GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET, BY TYPE
6.1. Market Snapshot
6.2. Global Uterine fibroid treatment drugs Market by Type, Performance - Potential Analysis
6.3. Global Uterine fibroid treatment drugs Market Estimates & Forecasts by Type 2020-2030 (USD Billion)
6.4. Uterine fibroid treatment drugs Market, Sub Segment Analysis
6.4.1. Subserosal Fibroids
6.4.2. Intramural Fibroids
6.4.3. Submucosal Fibroids
6.4.4. Pedunculated Fibroids
CHAPTER 7. GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET, BY END USER
7.1. Market Snapshot
7.2. Global Uterine fibroid treatment drugs Market by End User, Performance - Potential Analysis
7.3. Global Uterine fibroid treatment drugs Market Estimates & Forecasts by End User 2020-2030 (USD Billion)
7.4. Uterine fibroid treatment drugs Market, Sub Segment Analysis
7.4.1. Hospitals
7.4.2. Retail pharmacies
7.4.3. Other
CHAPTER 8. GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET, REGIONAL ANALYSIS
8.1. Top Leading Countries
8.2. Top Emerging Countries
8.3. Uterine fibroid treatment drugs Market, Regional Market Snapshot
8.4. North America Uterine fibroid treatment drugs Market
8.4.1. U.S. Uterine fibroid treatment drugs Market
8.4.1.1. Drug Class breakdown estimates & forecasts, 2020-2030
8.4.1.2. Type breakdown estimates & forecasts, 2020-2030
8.4.1.3. End User breakdown estimates & forecasts, 2020-2030
8.4.2. Canada Uterine fibroid treatment drugs Market
8.5. Europe Uterine fibroid treatment drugs Market Snapshot
8.5.1. U.K. Uterine fibroid treatment drugs Market
8.5.2. Germany Uterine fibroid treatment drugs Market
8.5.3. France Uterine fibroid treatment drugs Market
8.5.4. Spain Uterine fibroid treatment drugs Market
8.5.5. Italy Uterine fibroid treatment drugs Market
8.5.6. Rest of Europe Uterine fibroid treatment drugs Market
8.6. Asia-Pacific Uterine fibroid treatment drugs Market Snapshot
8.6.1. China Uterine fibroid treatment drugs Market
8.6.2. India Uterine fibroid treatment drugs Market
8.6.3. Japan Uterine fibroid treatment drugs Market
8.6.4. Australia Uterine fibroid treatment drugs Market
8.6.5. South Korea Uterine fibroid treatment drugs Market
8.6.6. Rest of Asia Pacific Uterine fibroid treatment drugs Market
8.7. Latin America Uterine fibroid treatment drugs Market Snapshot
8.7.1. Brazil Uterine fibroid treatment drugs Market
8.7.2. Mexico Uterine fibroid treatment drugs Market
8.8. Middle East & Africa Uterine fibroid treatment drugs Market
8.8.1. Saudi Arabia Uterine fibroid treatment drugs Market
8.8.2. South Africa Uterine fibroid treatment drugs Market
8.8.3. Rest of Middle East & Africa Uterine fibroid treatment drugs Market
CHAPTER 9. COMPETITIVE INTELLIGENCE
9.1. Key Company SWOT Analysis
9.1.1. Company
9.1.2. Company
9.1.3. Company
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Myovant Sciences Gmbh
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Recent Developments
9.3.2. Pfizer Inc.
9.3.3. Abbvie Inc.
9.3.4. Ferring B.v
9.3.5. AstraZeneca
9.3.6. Bayer AG
9.3.7. Amring Pharmaceuticals Inc.
9.3.8. Watson Pharma Inc.
9.3.9. Boston scientific corporation
9.3.10. Gynesonics Inc.
CHAPTER 10. RESEARCH PROCESS
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption
LIST OF TABLES
TABLE 1. Global Uterine fibroid treatment drugs Market, report scope
TABLE 2. Global Uterine fibroid treatment drugs Market estimates & forecasts by Region 2020-2030 (USD Billion)
TABLE 3. Global Uterine fibroid treatment drugs Market estimates & forecasts by Drug Class 2020-2030 (USD Billion)
TABLE 4. Global Uterine fibroid treatment drugs Market estimates & forecasts by Type 2020-2030 (USD Billion)
TABLE 5. Global Uterine fibroid treatment drugs Market estimates & forecasts by End User 2020-2030 (USD Billion)
TABLE 6. Global Uterine fibroid treatment drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 7. Global Uterine fibroid treatment drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 8. Global Uterine fibroid treatment drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 9. Global Uterine fibroid treatment drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 10. Global Uterine fibroid treatment drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 11. Global Uterine fibroid treatment drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 12. Global Uterine fibroid treatment drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 13. Global Uterine fibroid treatment drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 14. Global Uterine fibroid treatment drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 15. Global Uterine fibroid treatment drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 16. U.S. Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 17. U.S. Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 18. U.S. Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 19. Canada Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 20. Canada Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 21. Canada Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 22. UK Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 23. UK Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 24. UK Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 25. Germany Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 26. Germany Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 27. Germany Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 28. France Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 29. France Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 30. France Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 31. Italy Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 32. Italy Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 33. Italy Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 34. Spain Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 35. Spain Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 36. Spain Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 37. RoE Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 38. RoE Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 39. RoE Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 40. China Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 41. China Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 42. China Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 43. India Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 44. India Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 45. India Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 46. Japan Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 47. Japan Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 48. Japan Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 49. South Korea Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 50. South Korea Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 51. South Korea Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 52. Australia Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 53. Australia Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 54. Australia Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 55. RoAPAC Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 56. RoAPAC Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 57. RoAPAC Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 58. Brazil Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 59. Brazil Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 60. Brazil Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 61. Mexico Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 62. Mexico Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 63. Mexico Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 64. RoLA Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 65. RoLA Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 66. RoLA Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 67. Saudi Arabia Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 68. South Africa Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 69. RoMEA Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 70. List of secondary sources, used in the study of global Uterine fibroid treatment drugs Market
TABLE 71. List of primary sources, used in the study of global Uterine fibroid treatment drugs Market
TABLE 72. Years considered for the study
TABLE 73. Exchange rates considered
List of tables and figures are dummy in nature, final lists may vary in the final deliverable
TABLE 1. Global Uterine fibroid treatment drugs Market, report scope
TABLE 2. Global Uterine fibroid treatment drugs Market estimates & forecasts by Region 2020-2030 (USD Billion)
TABLE 3. Global Uterine fibroid treatment drugs Market estimates & forecasts by Drug Class 2020-2030 (USD Billion)
TABLE 4. Global Uterine fibroid treatment drugs Market estimates & forecasts by Type 2020-2030 (USD Billion)
TABLE 5. Global Uterine fibroid treatment drugs Market estimates & forecasts by End User 2020-2030 (USD Billion)
TABLE 6. Global Uterine fibroid treatment drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 7. Global Uterine fibroid treatment drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 8. Global Uterine fibroid treatment drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 9. Global Uterine fibroid treatment drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 10. Global Uterine fibroid treatment drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 11. Global Uterine fibroid treatment drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 12. Global Uterine fibroid treatment drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 13. Global Uterine fibroid treatment drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 14. Global Uterine fibroid treatment drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 15. Global Uterine fibroid treatment drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 16. U.S. Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 17. U.S. Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 18. U.S. Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 19. Canada Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 20. Canada Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 21. Canada Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 22. UK Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 23. UK Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 24. UK Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 25. Germany Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 26. Germany Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 27. Germany Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 28. France Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 29. France Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 30. France Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 31. Italy Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 32. Italy Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 33. Italy Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 34. Spain Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 35. Spain Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 36. Spain Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 37. RoE Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 38. RoE Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 39. RoE Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 40. China Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 41. China Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 42. China Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 43. India Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 44. India Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 45. India Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 46. Japan Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 47. Japan Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 48. Japan Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 49. South Korea Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 50. South Korea Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 51. South Korea Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 52. Australia Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 53. Australia Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 54. Australia Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 55. RoAPAC Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 56. RoAPAC Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 57. RoAPAC Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 58. Brazil Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 59. Brazil Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 60. Brazil Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 61. Mexico Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 62. Mexico Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 63. Mexico Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 64. RoLA Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 65. RoLA Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 66. RoLA Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 67. Saudi Arabia Uterine fibroid treatment drugs Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 68. South Africa Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 69. RoMEA Uterine fibroid treatment drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 70. List of secondary sources, used in the study of global Uterine fibroid treatment drugs Market
TABLE 71. List of primary sources, used in the study of global Uterine fibroid treatment drugs Market
TABLE 72. Years considered for the study
TABLE 73. Exchange rates considered
List of tables and figures are dummy in nature, final lists may vary in the final deliverable
LIST OF FIGURES
FIG 1. Global Uterine fibroid treatment drugs Market, research methodology
FIG 2. Global Uterine fibroid treatment drugs Market, Market estimation techniques
FIG 3. Global Market size estimates & forecast methods
FIG 4. Global Uterine fibroid treatment drugs Market, key trends 2022
FIG 5. Global Uterine fibroid treatment drugs Market, growth prospects 2023-2030
FIG 6. Global Uterine fibroid treatment drugs Market, porters 5 force model
FIG 7. Global Uterine fibroid treatment drugs Market, pest analysis
FIG 8. Global Uterine fibroid treatment drugs Market, value chain analysis
FIG 9. Global Uterine fibroid treatment drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 10. Global Uterine fibroid treatment drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 11. Global Uterine fibroid treatment drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 12. Global Uterine fibroid treatment drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 13. Global Uterine fibroid treatment drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 14. Global Uterine fibroid treatment drugs Market, regional snapshot 2020 & 2030
FIG 15. North America Uterine fibroid treatment drugs Market 2020 & 2030 (USD Billion)
FIG 16. Europe Uterine fibroid treatment drugs Market 2020 & 2030 (USD Billion)
FIG 17. Asia pacific Uterine fibroid treatment drugs Market 2020 & 2030 (USD Billion)
FIG 18. Latin America Uterine fibroid treatment drugs Market 2020 & 2030 (USD Billion)
FIG 19. Middle East & Africa Uterine fibroid treatment drugs Market 2020 & 2030 (USD Billion)
List of tables and figures are dummy in nature, final lists may vary in the final deliverable
FIG 1. Global Uterine fibroid treatment drugs Market, research methodology
FIG 2. Global Uterine fibroid treatment drugs Market, Market estimation techniques
FIG 3. Global Market size estimates & forecast methods
FIG 4. Global Uterine fibroid treatment drugs Market, key trends 2022
FIG 5. Global Uterine fibroid treatment drugs Market, growth prospects 2023-2030
FIG 6. Global Uterine fibroid treatment drugs Market, porters 5 force model
FIG 7. Global Uterine fibroid treatment drugs Market, pest analysis
FIG 8. Global Uterine fibroid treatment drugs Market, value chain analysis
FIG 9. Global Uterine fibroid treatment drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 10. Global Uterine fibroid treatment drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 11. Global Uterine fibroid treatment drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 12. Global Uterine fibroid treatment drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 13. Global Uterine fibroid treatment drugs Market by segment, 2020 & 2030 (USD Billion)
FIG 14. Global Uterine fibroid treatment drugs Market, regional snapshot 2020 & 2030
FIG 15. North America Uterine fibroid treatment drugs Market 2020 & 2030 (USD Billion)
FIG 16. Europe Uterine fibroid treatment drugs Market 2020 & 2030 (USD Billion)
FIG 17. Asia pacific Uterine fibroid treatment drugs Market 2020 & 2030 (USD Billion)
FIG 18. Latin America Uterine fibroid treatment drugs Market 2020 & 2030 (USD Billion)
FIG 19. Middle East & Africa Uterine fibroid treatment drugs Market 2020 & 2030 (USD Billion)
List of tables and figures are dummy in nature, final lists may vary in the final deliverable
